TY - JOUR AU - Boyd, N. F. AU - Guo, H. AU - Martin, L. J. PY - 2007 DA - 2007// TI - Mammographic density and the risk and detection of breast cancer JO - N Engl J Med VL - 356 ID - Boyd2007 ER - TY - JOUR AU - Vacek, P. M. AU - Geller, B. PY - 2004 DA - 2004// TI - A prospective study of breast cancer risk using routine mammographic breast density measurements JO - Cancer Epidemiol Biomark Prev VL - 13 ID - Vacek2004 ER - TY - JOUR AU - Sandberg, M. E. AU - Li, J. AU - Hall, P. PY - 2013 DA - 2013// TI - Change of mammographic density predicts the risk of contralateral breast cancer--a case-control study JO - Breast Cancer Res VL - 15 ID - Sandberg2013 ER - TY - JOUR AU - Li, J. AU - Humphreys, K. AU - Eriksson, L. PY - 2013 DA - 2013// TI - Mammographic density reduction is a prognostic marker of response to adjuvant tamoxifen therapy in postmenopausal patients with breast cancer JO - J Clin Oncol VL - 31 ID - Li2013 ER - TY - CHAP AU - Sickles, E. AU - D’Orsi, C. J. AU - Bassett, L. W. PY - 2013 DA - 2013// TI - ACR BI-RADS® mammography BT - ACR BI-RADS® atlas. - breast imaging reporting and data system PB - American College of Radiology CY - Reston ID - Sickles2013 ER - TY - JOUR AU - Sartor, H. AU - Lang, K. AU - Rosso, A. PY - 2016 DA - 2016// TI - Measuring mammographic density: comparing a fully automated volumetric assessment versus European radiologists' qualitative classification JO - Eur Radiol VL - 26 ID - Sartor2016 ER - TY - JOUR AU - Gweon, H. M. AU - Youk, J. H. AU - Kim, J. A. PY - 2013 DA - 2013// TI - Radiologist assessment of breast density by BI-RADS categories versus fully automated volumetric assessment JO - Am J Roentgenol VL - 201 ID - Gweon2013 ER - TY - JOUR AU - Eng, A. AU - Gallant, Z. AU - Shepherd, J. PY - 2014 DA - 2014// TI - Digital mammographic density and breast cancer risk: a case-control study of six alternative density assessment methods JO - Breast Cancer Res VL - 16 ID - Eng2014 ER - TY - JOUR AU - Wengert, G. J. AU - Helbich, T. H. AU - Kapetas, P. PY - 2018 DA - 2018// TI - Density and tailored breast cancer screening: practice and prediction - an overview JO - Acta Radiol Open VL - 7 ID - Wengert2018 ER - TY - JOUR AU - Spak, D. A. AU - Plaxco, J. S. AU - Santiago, L. PY - 2017 DA - 2017// TI - BI-RADS((R)) fifth edition: a summary of changes JO - Diagn Interv Imaging VL - 98 ID - Spak2017 ER - TY - JOUR AU - Murphy, B. L. AU - Day, C. N. AU - Hoskin, T. L. PY - 2018 DA - 2018// TI - Neoadjuvant chemotherapy use in breast Cancer is greatest in excellent responders: triple-negative and HER2+ subtypes JO - Ann Surg Oncol VL - 25 ID - Murphy2018 ER - TY - JOUR AU - Mieog, J. S. AU - Hage, J. A. AU - Velde, C. J. PY - 2007 DA - 2007// TI - Preoperative chemotherapy for women with operable breast cancer JO - Cochrane Database Syst Rev VL - 2007 ID - Mieog2007 ER - TY - JOUR AU - Minckwitz, G. AU - Untch, M. AU - Blohmer, J. U. PY - 2012 DA - 2012// TI - Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes JO - J Clin Oncol VL - 30 ID - Minckwitz2012 ER - TY - JOUR AU - Symmans, W. F. AU - Peintinger, F. AU - Hatzis, C. PY - 2007 DA - 2007// TI - Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy JO - J Clin Oncol VL - 25 ID - Symmans2007 ER - TY - JOUR AU - Huober, J. AU - Minckwitz, G. AU - Denkert, C. PY - 2010 DA - 2010// TI - Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study JO - Breast Cancer Res Treat VL - 124 ID - Huober2010 ER - TY - JOUR AU - Tao, M. AU - Chen, S. AU - Zhang, X. AU - Zhou, Q. PY - 2017 DA - 2017// TI - Ki-67 labeling index is a predictive marker for a pathological complete response to neoadjuvant chemotherapy in breast cancer: a meta-analysis JO - Medicine (Baltimore) VL - 96 ID - Tao2017 ER - TY - JOUR AU - Elsamany, S. AU - Alzahrani, A. AU - Abozeed, W. N. PY - 2015 DA - 2015// TI - Mammographic breast density: predictive value for pathological response to neoadjuvant chemotherapy in breast cancer patients JO - Breast VL - 24 ID - Elsamany2015 ER - TY - STD TI - Amin MB, American Joint Committee on Cancer American Cancer Society (2017) AJCC cancer staging manual, 8th edition/editor-in-chief, Mahul B. Amin, MD, FCAP ; editors, Stephen B. Edge, MD, FACS and 16 others ; Donna M. Gress, RHIT, CTR - Technical editor ; Laura R. Meyer, CAPM - Managing editor. edn. Chicago IL: American Joint Committee on Cancer, Springer. ID - ref18 ER - TY - JOUR AU - Rojas, K. I. AU - Flores, R. AU - Flores, C. J. PY - 2014 DA - 2014// TI - Mamographic density and disease-free survival in [HR+, HER2-] locally advanced breast cancer treated with neoadjuvant chemotherapy JO - J Clin Oncol VL - 32 UR - https://doi.org/10.1200/jco.2014.32.15_suppl.e11536 DO - 10.1200/jco.2014.32.15_suppl.e11536 ID - Rojas2014 ER - TY - JOUR AU - Vachon, C. M. AU - Kuni, C. C. AU - Anderson, K. PY - 2000 DA - 2000// TI - Association of mammographically defined percent breast density with epidemiologic risk factors for breast cancer (United States) JO - Cancer Causes Control VL - 11 ID - Vachon2000 ER - TY - JOUR AU - Colleoni, M. AU - Viale, G. AU - Zahrieh, D. PY - 2004 DA - 2004// TI - Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment JO - Clin Cancer Res VL - 10 ID - Colleoni2004 ER - TY - JOUR AU - Fisher, E. R. AU - Wang, J. AU - Bryant, J. PY - 2002 DA - 2002// TI - Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and bowel (NSABP) protocol B-18 JO - Cancer VL - 95 ID - Fisher2002 ER - TY - JOUR AU - Faneyte, I. F. AU - Schrama, J. G. AU - Peterse, J. L. PY - 2003 DA - 2003// TI - Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome JO - Br J Cancer VL - 88 ID - Faneyte2003 ER - TY - JOUR AU - Ring, A. E. AU - Smith, I. E. AU - Ashley, S. PY - 2004 DA - 2004// TI - Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer JO - Br J Cancer VL - 91 ID - Ring2004 ER - TY - JOUR AU - Guarneri, V. AU - Broglio, K. AU - Kau, S. W. PY - 2006 DA - 2006// TI - Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors JO - J Clin Oncol VL - 24 ID - Guarneri2006 ER - TY - JOUR AU - Sartor, H. AU - Borgquist, S. AU - Hartman, L. PY - 2015 DA - 2015// TI - Do pathological parameters differ with regard to breast density and mode of detection in breast cancer? The Malmo diet and Cancer study JO - Breast VL - 24 ID - Sartor2015 ER - TY - JOUR AU - Aiello, E. J. AU - Buist, D. S. AU - White, E. PY - 2005 DA - 2005// TI - Association between mammographic breast density and breast cancer tumor characteristics JO - Cancer Epidemiol Biomark Prev VL - 14 ID - Aiello2005 ER - TY - JOUR AU - Ghosh, K. AU - Brandt, K. R. AU - Sellers, T. A. PY - 2008 DA - 2008// TI - Association of mammographic density with the pathology of subsequent breast cancer among postmenopausal women JO - Cancer Epidemiol Biomark Prev VL - 17 ID - Ghosh2008 ER - TY - JOUR AU - Huo, C. W. AU - Chew, G. L. AU - Britt, K. L. PY - 2014 DA - 2014// TI - Mammographic density-a review on the current understanding of its association with breast cancer JO - Breast Cancer Res Treat VL - 144 ID - Huo2014 ER - TY - JOUR AU - Boyd, N. F. AU - Stone, J. AU - Martin, L. J. PY - 2002 DA - 2002// TI - The association of breast mitogens with mammographic densities JO - Br J Cancer VL - 87 ID - Boyd2002 ER - TY - JOUR AU - Lane, R. J. AU - Khin, N. Y. AU - Pavlakis, N. PY - 2018 DA - 2018// TI - Challenges in chemotherapy delivery: comparison of standard chemotherapy delivery to locoregional vascular mass fluid transfer JO - Future Oncol VL - 14 ID - Lane2018 ER - TY - JOUR AU - Cox, T. R. AU - Erler, J. T. PY - 2011 DA - 2011// TI - Remodeling and homeostasis of the extracellular matrix: implications for fibrotic diseases and cancer JO - Dis Model Mech VL - 4 ID - Cox2011 ER - TY - JOUR AU - Swartz, M. A. AU - Fleury, M. E. PY - 2007 DA - 2007// TI - Interstitial flow and its effects in soft tissues JO - Annu Rev Biomed Eng VL - 9 ID - Swartz2007 ER - TY - JOUR AU - Minchinton, A. I. AU - Tannock, I. F. PY - 2006 DA - 2006// TI - Drug penetration in solid tumours JO - Nat Rev Cancer VL - 6 ID - Minchinton2006 ER - TY - JOUR AU - Junttila, M. R. AU - Sauvage, F. J. PY - 2013 DA - 2013// TI - Influence of tumour micro-environment heterogeneity on therapeutic response JO - Nature VL - 501 ID - Junttila2013 ER - TY - JOUR AU - Boyd, N. F. AU - Dite, G. S. AU - Stone, J. PY - 2002 DA - 2002// TI - Heritability of mammographic density, a risk factor for breast cancer JO - N Engl J Med VL - 347 ID - Boyd2002 ER - TY - JOUR AU - Ursin, G. AU - Lillie, E. O. AU - Lee, E. PY - 2009 DA - 2009// TI - The relative importance of genetics and environment on mammographic density JO - Cancer Epidemiol Biomark Prev VL - 18 ID - Ursin2009 ER - TY - JOUR AU - Greendale, G. A. AU - Reboussin, B. A. AU - Sie, A. PY - 1999 DA - 1999// TI - Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Postmenopausal estrogen/progestin interventions (PEPI) investigators JO - Ann Intern Med VL - 130 ID - Greendale1999 ER - TY - JOUR AU - Brand, J. S. AU - Czene, K. AU - Eriksson, L. PY - 2013 DA - 2013// TI - Influence of lifestyle factors on mammographic density in postmenopausal women JO - PLoS One VL - 8 ID - Brand2013 ER - TY - JOUR AU - Mitchell, G. AU - Antoniou, A. C. AU - Warren, R. PY - 2006 DA - 2006// TI - Mammographic density and breast cancer risk in BRCA1 and BRCA2 mutation carriers JO - Cancer Res VL - 66 ID - Mitchell2006 ER - TY - JOUR AU - Boyd, N. F. AU - Martin, L. J. AU - Bronskill, M. PY - 2010 DA - 2010// TI - Breast tissue composition and susceptibility to breast cancer JO - J Natl Cancer Inst VL - 102 ID - Boyd2010 ER - TY - JOUR AU - Elsamany, S. AU - Alzahrani, A. AU - Elkhalik, S. A. PY - 2014 DA - 2014// TI - Prognostic value of mammographic breast density in patients with metastatic breast cancer JO - Med Oncol VL - 31 ID - Elsamany2014 ER - TY - JOUR AU - Banin Hirata, B. K. AU - Oda, J. M. AU - Losi Guembarovski, R. PY - 2014 DA - 2014// TI - Molecular markers for breast cancer: prediction on tumor behavior JO - Dis Markers VL - 2014 ID - Banin Hirata2014 ER - TY - JOUR AU - Mattos-Arruda, L. AU - Shen, R. AU - Reis-Filho, J. S. PY - 2016 DA - 2016// TI - Translating neoadjuvant therapy into survival benefits: one size does not fit all JO - Nat Rev Clin Oncol VL - 13 ID - Mattos-Arruda2016 ER - TY - JOUR AU - Yaghjyan, L. AU - Colditz, G. A. AU - Collins, L. C. PY - 2011 DA - 2011// TI - Mammographic breast density and subsequent risk of breast cancer in postmenopausal women according to tumor characteristics JO - J Natl Cancer Inst VL - 103 ID - Yaghjyan2011 ER - TY - JOUR AU - Ziv, E. AU - Tice, J. AU - Smith-Bindman, R. PY - 2004 DA - 2004// TI - Mammographic density and estrogen receptor status of breast cancer JO - Cancer Epidemiol Biomark Prev VL - 13 ID - Ziv2004 ER - TY - JOUR AU - Ma, H. AU - Luo, J. AU - Press, M. F. AU - Wang, Y. PY - 2009 DA - 2009// TI - Is there a difference in the association between percent mammographic density and subtypes of breast cancer? Luminal a and triple-negative breast cancer JO - Cancer Epidemiol Biomark Prev VL - 18 ID - Ma2009 ER - TY - STD TI - FDA. Guidance for industry: pathological complete response in neoadjuvant treatment of high-risk early-stage breast cancer: use as an endpoint to support accelerated approval. [http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm305501.pdf]. Accessed 19 Aug 2016. UR - http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm305501.pdf ID - ref48 ER - TY - JOUR AU - Mazouni, C. AU - Peintinger, F. AU - Wan-Kau, S. PY - 2007 DA - 2007// TI - Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome JO - J Clin Oncol VL - 25 ID - Mazouni2007 ER - TY - JOUR AU - Jones, R. L. AU - Lakhani, S. R. AU - Ring, A. E. PY - 2006 DA - 2006// TI - Pathological complete response and residual DCIS following neoadjuvant chemotherapy for breast carcinoma JO - Br J Cancer VL - 94 ID - Jones2006 ER - TY - JOUR AU - Park, C. K. AU - Jung, W. H. AU - Koo, J. S. PY - 2016 DA - 2016// TI - Pathologic evaluation of breast Cancer after Neoadjuvant therapy JO - J Pathol Transl Med VL - 50 ID - Park2016 ER - TY - JOUR AU - Geller, B. M. AU - Nelson, H. D. AU - Weaver, D. L. PY - 2017 DA - 2017// TI - Characteristics associated with requests by pathologists for second opinions on breast biopsies JO - J Clin Pathol VL - 70 ID - Geller2017 ER - TY - JOUR AU - Elmore, J. G. AU - Longton, G. M. AU - Carney, P. A. PY - 2015 DA - 2015// TI - Diagnostic concordance among pathologists interpreting breast biopsy specimens JO - JAMA VL - 313 ID - Elmore2015 ER - TY - JOUR AU - Alunni, J. P. PY - 2012 DA - 2012// TI - Imaging inflammatory breast cancer JO - Diagn Interv Imaging VL - 93 ID - Alunni2012 ER -